ArticleMaterials today. Bio2020
Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy.
Article in Materials today. Bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- A Non-Antigenic Randomized Polyethylene Glycol/Poly(2-Phenyl-2-Oxazine)-Based Drug Delivery Platform.Macromolecular rapid communications · 2026Article
- Review
- Advances in Polymeric Micelles: Responsive and Targeting Approaches for Cancer Immunotherapy in the Tumor Microenvironment.Pharmaceutics · 2023Review
- Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer.Cancers · 2023Review
- Macrophage's role in solid tumors: two edges of a sword.Cancer cell international · 2023Article
- Sexual dimorphism in gut microbiota dictates therapeutic efficacy of intravenous immunoglobulin on radiotherapy complications.Journal of advanced research · 2023Article
- Article
- Recent advances in cancer therapy using PARP inhibitors.Medical oncology (Northwood, London, England) · 2022Review
- Development of a G2/M arrest high-throughput screening method identifies potent radiosensitizers.Translational oncology · 2022Article
- Neutrophil Survival Signaling DuringFrontiers in cellular and infection microbiology · 2022Article
- Immunotherapies catering to the unmet medical need of cold colorectal cancer.Frontiers in immunology · 2022Review
- The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review).Biomedical reports · 2021Review
- Insight Into Nicotinamide Adenine Dinucleotide Homeostasis as a Targetable Metabolic Pathway in Colorectal Cancer.Frontiers in pharmacology · 2021Review
- Exploiting Phagocytic Checkpoints in Nanomedicine: Applications in Imaging and Combination Therapies.Frontiers in chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Multimodal therapy is often used in oncology to overcome dosing limitations and chemoresistance. Recently, combination immunoradiotherapy has shown great promise in a select subset of patients with colorectal cancer (CRC). Furthermore, molecularly targeted agents delivered in tandem with immunotherapy regimens have been suggested to improve treatment outcomes and expand the population of responding patients. In this study, radiation-sensitizing small molecules niraparib (PARP inhibitor) and HS-173 (PI3K inhibitor) are identified as a novel combination that synergistically enhance toxicity and induce immunogenic cell death both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.